Revolution Medicines Doubles Pancreatic Cancer Survival in Phase 3 Trial — Is RVMD Stock a Buy at $136?

On April 13th 2026, Revolution Medicines finally dropped the Phase 3 data from their global RASolute 302 trial testing daraxonrasib - a once-a-day oral pill that targets a type of mutation found in pancreatic cancer. And what did it reveal? Median total survival time was 13.2 months for people getting daraxonrasib, versus 6.7 months for those on standard chemo - a pretty stark difference. And the numbers were clear - a 60% reduction in the risk of death ( p < 0.0001 ) to be exact. They actually beat the trial's own co-primary endpoints and key secondary ones - the trial was even halted early because they knew they had a winner.

To put this in perspective: pancreatic cancer is pretty tough on people, with a 5 year survival rate of around 13% . And daraxonrasib specifically targets the driving force behind most cases - these RAS mutations that were previously thought to be untouchable. Before this data came out, the general consensus on the street was that daraxonrasib would give people about 10-11 months of total survival time. But what we got was 13.2 months - a big beat, by anyone's measure. And the volume of trades that day was pretty crazy - 14.1 million shares changed hands (that's roughly 5.5 times the 30 day average of 2.6 million) - that kind of action usually means the big players are taking a serious interest, not just some retail noise.

Now, they're gonna submit an NDA to the FDA and look to get priority review. They've also got a meeting lined up to share all the data at a future medical conference. And a first line trial - RASolute 303 - just started dosing on April 2nd 2026. So now they have a Phase 3 trial in both first line and second line treatment of pancreatic cancer covered.

The 4-hour chart paints a pretty clear picture of what's been going on with RVMD. It spent months stuck inside a tight descending symmetrical triangle - that's a classic sign of the market building up a sneaky load of buying pressure - before the Phase 3 catalyst finally broke the camel's back and propelled it above the falling resistance line near $95. As the impulse candle surged, it reclaimed all the key EMAs in one go, and to top it all off, it printed a brand new all-time high at $136.80 intraday. The RSI, meanwhile, was racing towards 60+ - a decent sign of momentum without quite getting to overbuying territory just yet.

RVMD (Revolution Medicines) Price Chart - Source: Tradingview

Yep, an initial resistance cluster around $136. Buyers would do well to be watching for a pullback to the $120-$125 zone, where the Fibonacci retracement levels are clustered. Once price has got back up to $125, the projected path suggests a continuation push towards $144.75 and $152 - but as long as price holds firm above $114, the big picture remains bullish. A close below that level and the breakout's busted - it's back to the range for RVMD.

On the day that Revolution Medicines announced the Phase 3 data, they also let everyone know that they're going to be raising some cash - a big chunk of cash, actually - by offering up some common stock and senior notes to help pay for the costs of getting daraxonrasib ready for the market, and then pushing it out there. We see this kind of move all the time after big biotech events, and the market wasn't exactly surprised - but it does tend to pull the stock price down by 5 to 15% as it absorbs the new supply. The thing is, the stock is being sold at what price relative to where we are today.

Fundamentally speaking, it's hard to argue against the bullish side of this story. Oppenheimer just upped their price target to $165, and gave it a "buy" rating. Leerink Partners did the same to $147. The rest of the analyst crowd had their target prices sitting at around $133 before this data came out - which means they're all going to be bumping them up pretty soon, especially when they see the data presented at the AACR conference in April and when they see the first quarter earnings come out in May. To put this in perspective, the American Cancer Society is saying there'll be around 66,440 new pancreatic cancer cases in the US in 2026 alone. And some of the analysts have been talking about how daraxonrasib could bring in between $2 and $4 billion a year in sales just for pancreatic cancer - not even counting all the other cancers where daraxonrasib is likely to be useful.

The reason RVMD went through the roof was that its Phase 3 RASolute 302 trial produced a 60% reduction in the risk of death versus chemo for pancreatic cancer - essentially a 0.40 hazard ratio with overall survival of 13.2 months as opposed to just 6.7 months for the standard of care. Not only did this smash through the Street's pre-readout expectations of 10-11 months, but Oppenheimer then jumped its target up to $165 and Leerink Partners followed suit with $147 - both of them still calling it an Outperform. Then there was the 14.1 million shares that changed hands - that's 5.5 times the 30 day average - and it all suggested that there was some serious behind the scenes institutional support driving the price up.

Well, post-data price targets from the analysts range from $147 courtesy of Leerink Partners to $165 courtesy of Oppenheimer, and both of them still believe in the company enough to rate it Outperform. The prior consensus number of $133.70 is now looking pretty old-fashioned, and with the AACR presentations coming up in April and Earnings day not until May 6, its probably going to go up. And technically if the stock can manage to hold above $136.80 for a bit, then it starts to open up a lot of possibilities from $144.75 to $152.

Typically when a biotech does a post-catalyst secondary offering, you get a 5-15% pullback while the market digests all that new stock. For RVMD the crucial support zone is $125 to $119.92 - that's the 0.382 to 0.5 fibonacci retracement and if the offering price ends up above $120, and that support zone holds then historically its been a pretty good buying opportunity. BUT - if the stock then drops below $114, that's a sign that the breakout has failed and you probably want out of that trade.